Value through Innovation27 July 2016

Clinical Study Results

  • Afatinib + Nintedanib - Prostatic Neoplasms
    Clinical Study Number 1239.3
    Study Indication Prostatic Neoplasms
    Product Afatinib + Nintedanib
    Generic Name Afatinib + Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A multi-centre 3-arm randomised phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer

    Study Document Trial synopsis 1239.3_DS_DR english
  • BI 2536 - Prostatic Neoplasms
    Clinical Study Number 1216.19
    Study Indication Prostatic Neoplasms
    Product BI 2536
    Generic Name BI 2536
    Lab Code
    Clinical Phase II
    Study Title

    A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic hormone-refractory prostate cancer

    Study Document Trial synopsis 1216.19_CO english
  • VARGATEF ® - Prostatic Neoplasms
    Clinical Study Number 1199.11
    Study Indication Prostatic Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase IIa
    Study Title

    Phase II trial of two dose levels BIBF 1120 in patients with advanced prostate cancer

    Study Document Trial synopsis 1199.11 english
  • VARGATEF ® - Prostatic Neoplasms
    Clinical Study Number 1199.4
    Study Indication Prostatic Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase Ib
    Study Title

    Phase I study of escalating doses of BIBF 1120 ES with docetaxel in patients with hormone refractory prostate cancer

    Study Document Trial synopsis 1199.4 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.